Supernus Pharmaceuticals, Inc. (SUPN) Q3 2015 Earnings Results

Supernus Pharmaceuticals Beats on EPS, Stock Up 3.25%

Supernus Pharmaceuticals reported a better-than-expected EPS of $0.08, leading to a 3.25% increase in stock price. The significant EPS surprise indicates strong cost management or operational efficiency, although the lack of revenue data leaves some uncertainty. Investors may view this performance positively, but the absence of guidance could lead to cautious sentiment in the near term.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.08	N/A	+233.33%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management conveyed a positive outlook on earnings, emphasizing their commitment to growth. However, they did not provide specific guidance for future quarters.

Management expressed satisfaction with the EPS performance despite not providing revenue figures.

They highlighted ongoing efforts in product development and market expansion.

Supernus Pharmaceuticals Beats on EPS, Stock Up 3.25%

Key numbers

Management commentary

Supernus Pharmaceuticals, Inc.

More earnings this week

Supernus Pharmaceuticals Beats on EPS, Stock Up 3.25%

Key numbers

Management commentary